Search results for: England
Filter search results
NICE ‘Optimised’ Recommendations: What Do They Mean for Patient Access?
30 July 2020
…Health Service (NHS) in England based on their clinical and cost-effectiveness, through their Technology Appraisal (TA) programme. Following review, the main TA outcomes are to ‘recommend’ the medicine (in line…
Establishing a Reasonable Price for an Orphan Drug
11 September 2020
…SMC and NICE define ultra-orphan drugs as medicines granted orphan status by the EMA and treating conditions with a prevalence of 1 in 50,000 people in England and/or Scotland –…
Opportunity Cost in Health Care: a Favourite Research Topic for OHE
23 November 2021
…led research on this top for many years, with a particular focus on cost-effectiveness thresholds. As the first empirical estimates of a cost-effectiveness threshold for England were published in 2013,…
New NICE Manual for Health Technology Evaluations: A Critical Discussion on the Most Relevant Changes (or Lack Thereof)
23 February 2022
…guidance and advice for health, public health, and social care practitioners. In England and Wales, new health technologies are appraised based on NICE guidance to determine whether they should be…
Invest to End TB. Save Lives. World TB Day 2022. Reflections on 60 years of OHE publications on TB
24 March 2022
…from 2015 levels in the 2021 TB Action Plan for England. Related Research Office of Health Economics (1962). Progress against Tuberculosis. Available from Progress against Tuberculosis (ohe.org) Marchant, N. (1998)…
The State of Play for Cost-effectiveness Thresholds
28 June 2022
…for England, Spain, and Australia have been available for several years, and yet these studies’ central estimates have not been adopted by policymakers. Part of the challenge is that the…
Health and the Use of Medicines in Primary Care in Wales
1 November 2011
…their medicines allocations, although the reasons remain unclear. At the same time, however, Wales lags behind England in the uptake of new primary and secondary care medicines that have received…
The Expanding Value Footprint of Oncology Treatments
1 May 2014
…treatment regimen, or patient population or subpopulation. The decisions of three entities were included in the study: the Haute Autorité de Santé (HAS) in France, NICE in England and Wales,…
Progress against Tuberculosis
1 October 1962
…the economic benefit to England and Wales resulting from the use of the anti-tubercular drugs alone is approximately £55 million a year, or more than half the cost of the…